IgA Nephropathy in the Elderly

Introduction: Knowledge about IgA nephropathy (IgAN) presentation and prognosis for elderly patients is limited. We assessed clinical and histologic findings among patients aged ≥ 60 years at diagnosis and examined factors associated with the risk of kidney failure and death. Methods: We identified those patients at our center between 1996 and 2020. Age, sex, race, chronic kidney disease (CKD) stage, and histologic MEST-C classification at biopsy were collected. Outcomes of kidney failure and death were ascertained by using United States Renal Data System (USRDS) and National Death Index (NDI), respectively. Associations of baseline predictors with kidney failure were examined by using cause-specific Cox hazards regression with all-cause mortality as competing risk. For all-cause mortality, standard Cox proportional hazards regression analysis was used. Cumulative survival probabilities were examined using Kaplan-Meier survival curves. Results: Among 127 patients, median estimated glomerular filtration rate (eGFR) was 25 ml/min per 1.73 m2, 81% had proteinuria ≥ 1000 mg/g creatinine, 35% and 17% had CKD stages 4 and 5, respectively. Forty-five patients progressed to kidney failure and 86 died. Overall, Kaplan-Meier estimate of median time to kidney failure was 11.3 years and to death was 7.5 years. Males were more likely to progress to kidney failure than females. Kidney failure strongly associated with CKD stages 3, 4, and 5 versus stages 1 or 2; findings remained unchanged after adjusting for histology. Mortality was associated with increasing age and advanced CKD. Conclusion: IgAN diagnosed at elderly age is associated with severe clinical phenotype and portends a poor prognosis because of high risk of kidney failure and death.

Abstract licence: CC BY-NC-ND

9 more references, whose wording the paper’s licence keeps private.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.